ストックスクリーナーアプリを入手
24.51
2.64%
0.63
アフターアワーズ：
24.50
-0.01
-0.04%
前日終値:
$23.88
開ける：
$23.6
24時間の取引高:
2.09M
Relative Volume:
0.56
時価総額：
$4.13B
収益：
$56.99M
当期純損益:
$-107.23M
株価収益率:
-29.89
EPS:
-0.8199
ネットキャッシュフロー:
$-142.55M
1週間 パフォーマンス:
-3.08%
1か月 パフォーマンス:
-7.96%
6か月 パフォーマンス:
+90.30%
1年 パフォーマンス:
+255.22%
1日の値動き範囲:
$22.91
$24.68
1週間の範囲:
$22.91
$26.34
52週間の値動き範囲:
$6.25
$34.39
Tango Therapeutics Inc Stock (TNGX) Company Profile
Compare TNGX vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
24.51 | 3.96B | 56.99M | -107.23M | -142.55M | -0.8199 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-02 | 開始されました | Canaccord Genuity | Buy |
| 2026-02-23 | 開始されました | Mizuho | Outperform |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2024-07-17 | 開始されました | Jefferies | Buy |
| 2024-04-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 開始されました | Piper Sandler | Overweight |
| 2023-12-08 | 開始されました | B. Riley Securities | Buy |
| 2022-10-20 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Tango Therapeutics Inc (TNGX) 最新ニュース
Farallon Capital Management Adds to Tango Therapeutics (TNGX) St - GuruFocus
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
Tango Therapeutics appoints Robert Azelby to Board of Directors - scanx.trade
HC Wainwright Issues Pessimistic Outlook for TNGX Earnings - MarketBeat
Research Analysts Issue Forecasts for TNGX Q2 Earnings - MarketBeat
Trv Gp Iv LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat
Trv Gp Vi LLC Takes Position in Tango Therapeutics, Inc. $TNGX - MarketBeat
TANGO THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $68 FROM $66 - Bitget
The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift - simplywall.st
Tango (TNGX) Earnings Numbers in Focus: The Headline Comparisons Are Near Their Estimates in the Current Update; Market Read: Shares Finish 0.59% Up for the Current SessionEPS Growth Report - Vinanet
Tango Therapeutics (NASDAQ:TNGX) Given New $68.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright raises Tango Therapeutics price target to $68 By Investing.com - Investing.com Canada
H.C. Wainwright raises Tango Therapeutics price target to $68 - Investing.com
Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Stifel reiterates Tango Therapeutics stock rating with $40 target - Investing.com
Stifel reiterates Tango Therapeutics stock rating with $40 target By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Early trial shows strong pancreatic cancer resp... - Pluang
Tango Therapeutics: Promising Early Data, But A Long Road Ahead - Seeking Alpha
Walleye Capital LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Tango Therapeutics (TNGX) investors report 0% beneficial ownership in latest 13G/A - Stock Titan
Tango Therapeutics (TNGX): TCG Crossover and Chen Yu disclose 7% beneficial stake - Stock Titan
Goldman Sachs Group (TNGX) discloses 6.0% beneficial stake in Tango Therapeutics - Stock Titan
Woodline holds 4.0M Tango Therapeutics (TNGX) shares, a 2.5% stake - Stock Titan
Farallon group discloses 16.27M Tango Therapeutics (TNGX) shares and warrants - Stock Titan
Handelsbanken Fonder AB Acquires Shares of 287,900 Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics Insiders Selling US$727k In Stock Relieved As Market Cap Slides To US$4.4b - Moomoo
Tema ETFs LLC Buys New Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (NASDAQ:TNGX): What Does the Latest Update Mean for Clinical Progress? - Kalkine Media
Tango Therapeutics, Inc. (TNGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tango Therapeutics Expands At-The-Market Equity Program - The Globe and Mail
Tango Therapeutics Inc (TNGX) News, Articles, Events & Latest Updates - Stocktwits
Adage Capital discloses 3.44% Tango Therapeutics (TNGX) stake in 13G/A filing - Stock Titan
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses - The Globe and Mail
Wedbush Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $39 - Moomoo
Guggenheim raises Tango Therapeutics stock price target to $35 By Investing.com - Investing.com South Africa
Guggenheim raises Tango Therapeutics stock price target to $35 - Investing.com Nigeria
Tango Therapeutics (TNGX) Stock Faces Cash Burn Pressure After Revenue Vanishes - Sahm
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $44.58, Implies 61% Upside - TradingView
Tango TherapeuticsFiles Prospectus To Sell Up To $400 Million In Common Stock - TradingView
Tango Therapeutics (TNGX) ups at-the-market stock capacity to $400M with new supplement - Stock Titan
Why is Tango Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Tango Therapeutics Q2 Results: EPS misses estimate, losses widen YoY - scanx.trade
Tango Therapeutics faces earnings test as PRMT5 data fuels rally By Investing.com - Investing.com Australia
Tango Therapeutics faces earnings test as PRMT5 data fuels rally - Investing.com Nigeria
Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results - MarketBeat
Form 8K Tango Therapeutics Inc For: 11 August By Investing.com - Investing.com South Africa
Form 8K Tango Therapeutics Inc For: 11 August - Investing.com Nigeria
Tango Therapeutics Q2 Net Loss Widens - marketscreener.com
Tango Therapeutics Reports Q2 Net Loss and $1 Billion Cash Position - Quiver Quantitative
Tango Therapeutics Inc (TNGX) 財務データ
収益
当期純利益
現金流量
EPS
0.00%
3.22%
大文字化:
|
ボリューム (24 時間):